This condition, called albuminuria, is a sign that the kidneys are not functioning normally.

They recommend that therapy should be considered at the higher level in people at high risk for stroke, retinopathy, and progression of albuminuria.

He writes that these “failed” trials “suggest that improvement in surrogate markers — lower blood pressure or less albuminuria — does not translate into risk reduction.”